Key points are not available for this paper at this time.
This study aims to assess the liquidity position of selected pharmaceutical companies before and after the COVID-19 pandemic. Utilizing liquidity ratio data from 2018 to 2022, the research evaluates changes in financial health for companies like Sun Pharma, Aurobindo Pharma, Lupin Ltd, Cipla Ltd, Dr. Reddy, Cadila Healthcare, Glenmark, Torrent Pharma, Alkem Laboratories, and Divis Lab. The analysis highlights a mixed response in liquidity positions, with some measures showing slight decreases while others display significant increases post-pandemic. The findings suggest that while certain aspects of liquidity have improved, overall stability varies across different financial metrics. The findings of this study are expected to contribute to the existing literature on financial performance in the pharmaceutical sector during global crises, offering valuable insights for investors, policymakers, and corporate managers. Keywords: Pharmaceuticals Industry, Covid19, Financial Ratios, India.
Abhijit Roy (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: